Results from Qu Biologics’ Crohn’s Disease RESTORE Trial Selected for Oral Presentation at ECCO 2021
June 09, 2021 09:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Qu Biologics Files Important New IP for the Treatment of Post-Surgical Immune Dysfunction and Prevention of Cancer Metastasis
May 12, 2021 09:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, May 12, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform...
Positive Signals for Endoscopic and Histologic Response in Patients with Crohn’s Disease Treated with Qu Biologics’ QBECO
January 04, 2021 09:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platform
December 18, 2020 13:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
Qu Biologics Completes $8M Financing
December 09, 2020 06:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
Qu Biologics is pleased to announce the appointment of Karn Manhas to Qu’s Board of Directors
August 24, 2020 06:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
Qu Biologics Initiates Phase 2 Study to Assess Activation of Anti-cancer Immune Response in Colon Cancer
August 18, 2020 14:35 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies...
Qu Biologics publishes landmark studies showing cells of the innate immune system can be directed to target organ sites to prevent and clear pathology and infection
April 06, 2020 06:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, April 06, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...
Qu Biologics Completes Enrollment in First Stage of Phase 2 Clinical Trial in Moderate to Severe Crohn’s Disease
December 18, 2019 17:35 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform...
Qu Biologics publishes potentially paradigm-shifting results of their first randomized-placebo controlled trial for the treatment of Crohn’s disease
July 23, 2019 06:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, July 23, 2019 (GLOBE NEWSWIRE) -- Qu Biologics Inc. (Qu), a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of...